This renewal application proposes to continue the investigation of vitamin D hormone (1,25(OH)2D3) action as mediated by its nuclear receptor, with a new emphasis on the functional interplay between 1,25(OH)2D3 and sex steroids in regulating bone remodeling. In the last grant period we succeeded in the molecular cloning of cDNAs to the avian and human vitamin D receptors (cVDR and hVDR) and we plan to expand upon these finding by: i) isolating the natural gene for cVDR and using intronic probes to study its nutritional and developmental control in relation to the major vitamin D induced protein in chickens, CaBP28k and ii) expressing hVDR both by in vitro transcription/translation and in E. coli in order to probe its zinc content,phosphorylation on serine residues, potential dimerization, and specific association with vitamin D responsive elements (VDREs) in genes such as osteocalcin/bone gla protein (BGP), vitamin D-24-OHase and type I collagen. Candidate 1,25(OH)2D3 hormone binding mutant VDRs from LLC-MK2 cells and a kindred with vitamin D resistance will also be characterized at the molecular biological level employing polymerase chain reaction. Concurrently, we plan to extend our published observation of estrogen receptors and effects on TGF-beta and collagen mRNA levels in osteoblast- like cells. Putative estrogen receptors (ER) in normal human osteoblasts will be further analyzed by immunochemical visualization and antagonist affinity labeling with tamoxifen aziridine. Recent collaborative experiments indicate that cotransfected hVDR confers 1,25(OH)2D3 responsiveness to a reporter-linked estrogen responsive element (ERE) palindrome. Therefore, estrogen and 1,25(OH)2D3 bind to a functionally overlapping subfamily of the steroid, thyroid and retinoid superfamily of receptors. We propose to exploit this new insight and utilize normal human bone cells to elucidate the mechanism whereby sex steroids and 1,25(OH)2D3 modulate autocrine and paracrine growth factor (i.e. TGF-beta, IGFI, IGFII, etc.) influence on osteoblasts and their coupling to osteoclasts and bone marrow/thymus derived cells of the immune system in the concerted process of bone remodeling. The relationship of VDR and ER to their respective DNA recognition sites, VDRE and ERE, will be probed in bone cell expressed genes such as type I collagen, BGP and several relevant growth factors. These investigations should not only lead us to the VDRE switch in controlled genes, but they may also unveil the basic mechanisms of certain vitamin D resistant bone and mineral diseases as well as possibly clarify the molecular pathogenesis of postmenopausal osteoporosis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37AR015781-21
Application #
3481409
Study Section
General Medicine B Study Section (GMB)
Project Start
1975-01-01
Project End
1994-12-31
Budget Start
1992-01-01
Budget End
1992-12-31
Support Year
21
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
Schools of Medicine
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Jurutka, P W; Remus, L S; Whitfield, G K et al. (2000) The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB. Mol Endocrinol 14:401-20
Thompson, P D; Jurutka, P W; Haussler, C A et al. (1998) Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric receptor interactions. J Biol Chem 273:8483-91
Haussler, M R; Haussler, C A; Jurutka, P W et al. (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 154 Suppl:S57-73
Jurutka, P W; Hsieh, J C; Remus, L S et al. (1997) Mutations in the 1,25-dihydroxyvitamin D3 receptor identifying C-terminal amino acids required for transcriptional activation that are functionally dissociated from hormone binding, heterodimeric DNA binding, and interaction with basal transcription facto J Biol Chem 272:14592-9
Whitfield, G K; Selznick, S H; Haussler, C A et al. (1996) Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. Mol Endocrinol 10:1617-31
Jurutka, P W; Hsieh, J C; Nakajima, S et al. (1996) Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. Proc Natl Acad Sci U S A 93:3519-24
Nakajima, S; Hsieh, J C; Jurutka, P et al. (1996) Examination of the potential functional role of conserved cysteine residues in the hormone binding domain of the human 1,25-dihydroxyvitamin D3 receptor. J Biol Chem 271:5143-9
Ray, R; Swamy, N; MacDonald, P N et al. (1996) Affinity labeling of the 1 alpha,25-dihydroxyvitamin D3 receptor. J Biol Chem 271:2012-7
Hsieh, J C; Nakajima, S; Galligan, M A et al. (1995) Receptor mediated genomic action of the 1,25(OH)2D3 hormone: expression of the human vitamin D receptor in E. coli. J Steroid Biochem Mol Biol 53:583-94
Whitfield, G K; Hsieh, J C; Jurutka, P W et al. (1995) Genomic actions of 1,25-dihydroxyvitamin D3. J Nutr 125:1690S-1694S

Showing the most recent 10 out of 38 publications